# KEYNOTE-676 (NCT03711032)

> Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: high-risk non-muscle invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03711032
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: High-risk Non-muscle Invasive Bladder Cancer
- Interventions: Pembrolizumab; BCG
- Enrollment: 1397
- Primary outcome: Complete Response Rate (CRR) by Blinded Independent Central Review (BICR) (Cohort A)
- Primary outcome: Event-Free Survival (EFS) (Cohort B)

## Indexed commentary on KEYNOTE-676 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 20 YouTube videos
- 19 posts on X
- 11 podcast episodes

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=keynote-676-nct03711032

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03711032", "email": "<work email>"}; the inbox owner confirms by the emailed link.